×
The Standard e-Paper
Join Thousands Daily
The Standard Group Plc is a
multi-media organization with investments in media platforms spanning newspaper
print operations, television, radio broadcasting, digital and online services. The
Standard Group is recognized as a leading multi-media house in Kenya with a key
influence in matters of national and international interest.
Kenya recently entered a promising new phase in HIV prevention with the introduction of Lenacapavir, a long-acting medicine designed to reduce the risk of HIV infection. The development generated excitement in the public space, as it should. New tools are critical in the ongoing fight against HIV.
But amid the enthusiasm, one point needs to be clarified: Lenacapavir is not a vaccine. It is a preventive medicine given to people who do not have HIV to help reduce their risk of infection. This approach is known as pre-exposure prophylaxis, or PrEP. Unlike daily oral PrEP tablets that must be taken regularly, Lenacapavir is administered as an injection every six months.
Subscribe to our newsletter and stay updated on the latest developments and special offers!
join